Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.
Thromboxane A2 (TXA2) plays a pivotal role in platelet activation and is involved in the development of thrombosis. Thromboxane synthase inhibitors suppress TXA2 formation and increase the synthesis of the antiaggregatory prostaglandins PGI2 and PGD2; however, accumulated PGH2 may interact with the platelet and vessel wall TXA2 receptor, thus reducing the antiplatelet effects of this class of drug. TXA2 receptor antagonists block the activity of both TXA2 and PGH2 on platelets and the vessel wall. Very recently, drugs possessing both thromboxane synthase-inhibitory and thromboxane receptor-antagonist properties have been developed. Paolo Gresele and colleagues explain here why these drugs can be more efficacious than traditional antiplatelet agents and review the available experimental studies involving these drugs.
Gresele
P
P
Istituto di Semeiotica Medica, University of Perugia, Italy.
Deckmyn
H
H
Nenci
G G
GG
Vermylen
J
J
D000818:Animals; D006801:Humans; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D017482:Receptors, Thromboxane; D013927:Thrombosis / Q000188:drug therapy*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013930:Thromboxane-A Synthase